- Home
- GDST vs TOVX Comparison
GDST vs TOVX Comparison
Compare GDST & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDST
- TOVX
- Stock Information
- Founded
- GDST 2020
- TOVX 2001
- Country
- GDST United States
- TOVX United States
- Employees
- GDST N/A
- TOVX N/A
- Industry
- GDST
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- GDST
- TOVX Health Care
- Exchange
- GDST NYSE
- TOVX Nasdaq
- Market Cap
- GDST N/A
- TOVX 3.5M
- IPO Year
- GDST 2022
- TOVX 2006
- Fundamental
- Price
- GDST $11.29
- TOVX $1.14
- Analyst Decision
- GDST
- TOVX Strong Buy
- Analyst Count
- GDST 0
- TOVX 1
- Target Price
- GDST N/A
- TOVX $6.00
- AVG Volume (30 Days)
- GDST 125.0
- TOVX 96.3K
- Earning Date
- GDST 01-01-0001
- TOVX 11-12-2024
- Dividend Yield
- GDST N/A
- TOVX N/A
- EPS Growth
- GDST 111.15
- TOVX N/A
- EPS
- GDST 0.23
- TOVX N/A
- Revenue
- GDST N/A
- TOVX N/A
- Revenue This Year
- GDST N/A
- TOVX N/A
- Revenue Next Year
- GDST N/A
- TOVX N/A
- P/E Ratio
- GDST $49.87
- TOVX N/A
- Revenue Growth
- GDST N/A
- TOVX N/A
- 52 Week Low
- GDST $10.73
- TOVX $1.14
- 52 Week High
- GDST $12.45
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- GDST 80.29
- TOVX 36.15
- Support Level
- GDST N/A
- TOVX $1.23
- Resistance Level
- GDST $11.31
- TOVX $1.21
- Average True Range (ATR)
- GDST 0.00
- TOVX 0.07
- MACD
- GDST 0.01
- TOVX 0.01
- Stochastic Oscillator
- GDST 81.82
- TOVX 0.00
About GDST GOLDENSTONE ACQUISITION LIMITED
Goldenstone Acquisition Ltd is a newly organized blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.